Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two …
A Kulagin, I Lisukov, M Ivanova… - British journal of …, 2014 - Wiley Online Library
Paroxysmal nocturnal haemoglobinuria ( PNH ) clones are frequently detected in patients
with aplastic anaemia ( AA ). To evaluate the prognostic role of PNH clone presence we …
with aplastic anaemia ( AA ). To evaluate the prognostic role of PNH clone presence we …
Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis
…, K Kałwak, C Klein, A Kulagin… - Blood, The Journal …, 2022 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment
for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have …
for patients affected by Wiskott-Aldrich syndrome (WAS). Reported HSCT outcomes have …
Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria …
…, JH Jang, P Hillmen, AD Kulagin… - British journal of …, 2020 - Wiley Online Library
Ravulizumab, a novel long‐acting complement component 5 (C5) inhibitor administered
every 8 weeks (q8w), was non‐inferior to eculizumab for all efficacy outcomes in two …
every 8 weeks (q8w), was non‐inferior to eculizumab for all efficacy outcomes in two …
[HTML][HTML] Immunosuppressive microenvironment and efficacy of PD-1 inhibitors in relapsed/refractory classic Hodgkin lymphoma: checkpoint molecules landscape and …
…, I Moiseev, N Mikhailova, V Baykov, A Kulagin - Cancers, 2021 - mdpi.com
Simple Summary Classic Hodgkin lymphoma contains rare malignant Hodgkin/Reed–Sternberg
cells and abundant reactive populations in the tumor microenvironment. Many aspects …
cells and abundant reactive populations in the tumor microenvironment. Many aspects …
[HTML][HTML] High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis
…, VY Melnichenko, DA Fedorenko, AD Kulagin… - Experimental …, 2008 - Elsevier
High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic stem cell
transplantation (auto-HSCT) is a new and promising approach to the treatment of multiple …
transplantation (auto-HSCT) is a new and promising approach to the treatment of multiple …
[HTML][HTML] Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab
AD Kulagin, VV Ptushkin, EA Lukina, IL Davydkin… - Annals of …, 2021 - Springer
Currently, eculizumab is the main effective treatment for paroxysmal nocturnal hemoglobinuria
(PNH). The aim of this randomized multicenter noninferiority study was to evaluate the …
(PNH). The aim of this randomized multicenter noninferiority study was to evaluate the …
Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studies
…, S Langemeijer, K Usuki, A Kulagin… - European Journal of …, 2022 - Wiley Online Library
Objectives The complement component 5 (C5) inhibitor ravulizumab demonstrated non‐inferiority
to eculizumab following 26 weeks of treatment in complement inhibitor‐naïve and …
to eculizumab following 26 weeks of treatment in complement inhibitor‐naïve and …
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single‐lineage marrow failure: a pilot study and a survey from the EBMT …
An alemtuzumab‐based experimental immunosuppressive treatment (IST) regimen was
investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure …
investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure …
[HTML][HTML] Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease …
…, JL Piñana, F Ciceri, H Sengeloev, A Kulagin… - Frontiers in …, 2023 - frontiersin.org
Introduction COVID-19 has been associated with high morbidity and mortality in allogeneic
hematopoietic stem cell transplant (allo-HCT) recipients. Methods This study reports on 986 …
hematopoietic stem cell transplant (allo-HCT) recipients. Methods This study reports on 986 …
[HTML][HTML] Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute …
…, AM Raiola, E Angelucci, AD Kulagin… - Bone Marrow …, 2023 - nature.com
For patients with acute myeloid and lymphoblastic leukaemia (AML/ALL) lacking a matched
sibling or unrelated donor, haploidentical stem cell transplantation (HAPLO-SCT) is …
sibling or unrelated donor, haploidentical stem cell transplantation (HAPLO-SCT) is …